Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

Trial Profile

Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Mar 2016 According to ClinicalTrials.gov record, the primary end point has been amended and hence the trial focus has changed to TU and AR
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top